An update from Resonance Health Ltd ( (AU:RHT) ) is now available.
Resonance Health Ltd reported record cash receipts of $14.9M over the last 12 months, with a positive cash flow from operations. The company completed a cost efficiency program, resulting in significant annual savings, and is progressing with major clinical trials and contract extensions in its SaMD business. The TrialsWest division is set for strong growth with new contracts and expanded capacity. The company is enhancing automation and efficiency to serve more customers at a lower cost, expecting annual savings of approximately $1.1M.
More about Resonance Health Ltd
Resonance Health Ltd operates in the healthcare industry, focusing on clinical trial management, software-as-a-medical-device image analysis services, and clinical trial site services. The company is engaged in providing clinical trial management services, developing software for medical imaging, and offering trial site services, primarily catering to global pharmaceutical companies.
YTD Price Performance: -20.0%
Average Trading Volume: 372,955
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$18.38M
For detailed information about RHT stock, go to TipRanks’ Stock Analysis page.